OpenNeedle Ask your own

Question explored with the scientific record

Are stents beneficial

Sep 10, 2026 · 5 sources used · OpenNeedle synthesis
The short version: stents are a mechanical fix for a plumbing problem, but the evidence shows they reduce the need for repeat procedures more than they prevent heart attacks or death.

The evidence here is almost entirely about patients who already had a heart attack or were getting a stent. None of these studies compare stenting to the best medical therapy alone—diet, exercise, statins, blood pressure control, and smoking cessation. That is the comparison that would tell you whether the stent itself saves lives. Without it, you are comparing one stent to another stent, or a stent to balloon angioplasty, and the benefit is mostly about keeping the artery open longer, not about living longer.

What the studies do show: drug-eluting stents (DES) reduce the chance you will need another procedure on the same spot compared to bare-metal stents (BMS). In one large registry of STEMI patients, DES cut the need for repeat procedures from about 9 in 100 to about 7 in 100 over two years [4]. But the same study found no difference in death or heart attack between the two types of stents [4]. Another study in diabetics with left main disease found DES lowered repeat procedures but did not change death or heart attack rates after adjustment [3].

The real risks are not small. Stent thrombosis—a blood clot inside the stent—happens in about 4 in 100 patients after a heart attack, and when it does, about 29 in 100 of those patients die [2]. Very late stent thrombosis (more than a year after placement) was about 6 times more common with drug-eluting stents than bare-metal stents in one study [4]. Stent fracture occurs in about 4 in 100 stents and is linked to higher rates of restenosis and repeat procedures [5]. Contrast dye used during placement can damage kidneys, especially in people with borderline kidney function [1].

OutcomeDrug-eluting stentBare-metal stentWhat it means
Repeat procedure at 2 years (STEMI)7.2%8.7%DES modestly reduces need for re-do [4]
Death at 2 years (STEMI)7.8%11.4%Difference not significant after adjustment [4]
Very late stent thrombosis0.4%0.06%6.7x higher with DES [4]
Stent thrombosis after heart attack3.7% overall29% mortality if it happens [2]

My call: stents are beneficial for relieving symptoms and preventing repeat procedures in people with significant blockages, but the evidence does not show they prevent heart attacks or death better than good medical management alone. The risks of stent thrombosis, contrast kidney injury, and the need for long-term blood thinners are real and understated in most discussions. Confidence: moderate for the symptom and re-stenosis benefit, low for any survival benefit over medical therapy alone.

Keep digging

Sources used 5

  1. Role of Hydration in Contrast-Induced Nephropathy in Patients Who Underwent Primary Percutaneous Coronary Intervention The American Journal of Cardiology (2015) Thin

    This study investigates the effectiveness of intravenous hydration with isotonic saline in preventing contrast-induced nephropathy (CIN) in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, finding that hydration sign…

    DOI: 10.1016/j.amjcard.2015.02.004
  2. Incidence, Implications, and Predictors of Stent Thrombosis in Acute Myocardial Infarction The American Journal of Cardiology (2016) Thin

    This study investigates the incidence, implications, and predictors of stent thrombosis in patients with acute myocardial infarction who underwent percutaneous coronary intervention, revealing a 3.7% incidence of stent thrombosis and identifying several independent predictors in…

    DOI: 10.1016/j.amjcard.2016.02.029
  3. Long‐term clinical benefit of drug‐eluting stents over bare‐metal stents in diabetic patients with de novo left main coronary artery disease: Results from a real‐world multicenter registry Catheterization and Cardiovascular Interventions (2009) Thin

    This multicenter real-world registry study compares drug-eluting stents (DES) versus bare-metal stents (BMS) in diabetic patients with de novo left main coronary artery disease undergoing PCI, finding lower target lesion revascularization with DES and no increased death or myoca…

    DOI: 10.1002/ccd.21845
  4. Clinical Outcome After Primary Percutaneous Coronary Intervention With Drug-Eluting and Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction Circulation: Cardiovascular Interventions (2008) Thin

    In STEMI patients treated with primary PCI, drug-eluting stents reduced target lesion revascularization at 2 years compared with bare-metal stents, with similar overall risks of stent thrombosis, myocardial infarction, and death, though very late stent thrombosis was more freque…

    DOI: 10.1161/circinterventions.108.794578
  5. Meta-Analysis of Incidence, Clinical Characteristics and Implications of Stent Fracture The American Journal of Cardiology (2010) Thin

    This meta-analysis evaluates the incidence, predictors, and clinical outcomes of stent fractures, revealing a mean incidence of 4.0% and significant associations with in-stent restenosis and target lesion revascularization.

    DOI: 10.1016/j.amjcard.2010.06.010

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question